Shinya Sato

13PUBLICATIONS
18CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Traditional Chinese medicine and treatmentsMedical infection agents (incl. prions)Clinimetrics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Oct 28, 2026
von Willebrand Factor and ADAMTS13 Predict Therapeutic Efficacy and Severe Adverse Events in Advanced Hepatocellular Carcinoma Treated With Atezolizumab-Bevacizumab.

|Oct 16, 2026
Clinical Outcomes of Endoscopic Treatment for Asymptomatic and Symptomatic Common Bile Duct Stones: Incidence and Risk Factors for Post-ERCP Pancreatitis.

|Aug 13, 2026
Correction: Nishimura et al. Rifaximin Attenuates Liver Fibrosis and Hepatocarcinogenesis in a Rat MASH Model by Suppressing the Gut-Liver Axis and Epiregulin-IL-8-Associated Angiogenesis. Int. J. Mol. Sci. 2025, 26, 6710.

|Jul 28, 2026
Bovine Milk-Derived Extracellular Vesicles Ameliorate Steatohepatitis by Restoring Gut Barrier in CDA-HFD-Fed Mice.

|Feb 27, 2026
Creatinine/Cystatin C Ratio as a Surrogate Marker for Sarcopenia in Hepatitis-C-Associated Liver Cirrhosis After Achieving a Sustained Virologic Response.

Aritoshi Koizumi, Tadashi Namisaki, Akihiko Shibamoto

|Dec 30, 2025
Diabetes as a Risk Factor for Sarcopenia in Patients with MASH-Related Cirrhosis.

Shinya Sato, Hiroaki Takaya, Tadashi Namisaki

Pageof 3

Frequent Collaborators

13 joint publications

Tadashi Namisaki

11 joint publications

Norihisa Nishimura

11 joint publications

Koh Kitagawa

7 joint publications

Satoshi Iwai